In last trading session, Viracta Therapeutics Inc (NASDAQ:VIRX) saw 0.33 million shares changing hands with its beta currently measuring 0.88. Company’s recent per share price level of $1.15 trading at -$0.02 or -1.71% at ring of the bell on the day assigns it a market valuation of $45.16M. That closing price of VIRX’s stock is at a discount of -106.96% from its 52-week high price of $2.38 and is indicating a premium of 62.61% from its 52-week low price of $0.43. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.16 million shares which gives us an average trading volume of 99.60K if we extend that period to 3-months.
Viracta Therapeutics Inc (NASDAQ:VIRX) trade information
Upright in the red during last session for losing -1.71%, in the last five days VIRX remained trading in the green while hitting it’s week-highest on Friday, 04/12/24 when the stock touched $1.15 price level, adding 12.21% to its value on the day. Viracta Therapeutics Inc’s shares saw a change of 101.75% in year-to-date performance and have moved 12.75% in past 5-day. Viracta Therapeutics Inc (NASDAQ:VIRX) showed a performance of 21.05% in past 30-days. Number of shares sold short was 0.65 million shares which calculate 5.88 days to cover the short interests.
Viracta Therapeutics Inc (VIRX) estimates and forecasts
Statistics highlight that Viracta Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 57.53% of value to its shares in past 6 months, showing an annual growth rate of 3.03% while that of industry is 9.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -12.50% in the current quarter and calculating -12.50% decrease in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 44.96% during past 5 years.
VIRX Dividends
Viracta Therapeutics Inc is more likely to be releasing its next quarterly report between May 06 and May 10 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Viracta Therapeutics Inc (NASDAQ:VIRX)’s Major holders
Insiders are in possession of 2.88% of company’s total shares while institution are holding 52.79 percent of that, with stock having share float percentage of 54.36%. Investors also watch the number of corporate investors in a company very closely, which is 52.79% institutions for Viracta Therapeutics Inc that are currently holding shares of the company. BVF Inc. is the top institutional holder at VIRX for having 3.61 million shares of worth $5.1 million. And as of Jun 29, 2023, it was holding 9.37% of the company’s outstanding shares.
The second largest institutional holder is Citadel Advisors Llc, which was holding about 1.52 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 3.94% of outstanding shares, having a total worth of $2.14 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 0.81 million shares of worth $1.15 million or 2.11% of the total outstanding shares. The later fund manager was in possession of 0.27 million shares on Jun 29, 2023, making its stake of worth around $0.38 million in the company or a holder of 0.70% of company’s stock.
